A new kind of drugmaker is emerging to meet demand for lower-priced medicines by custom-making drugs, sparking pushback from federal health regulators and legal challenges from traditional pharmaceutical companies.
from WSJ.com: US Business https://ift.tt/2wZanuv
via IFTTT
No comments:
Post a Comment